Literature DB >> 12927545

Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies.

Tomoyuki Tanaka1, M Natividad Lobato, Terence H Rabbitts.   

Abstract

There is a major need in target validation and therapeutic applications for molecules that can interfere with protein function inside cells. Intracellular antibodies (intrabodies) can bind to specific targets in cells but isolation of intrabodies is currently difficult. Intrabodies are normally single chain Fv fragments comprising variable domains of the immunoglobulin heavy (VH) and light chains (VL). We now demonstrate that single VH domains have excellent intracellular properties of solubility, stability and expression within the cells of higher organisms and can exhibit specific antigen recognition in vivo. We have used this intracellular single variable domain (IDab) format, based on a previously characterised intrabody consensus scaffold, to generate diverse intrabody libraries for direct in vivo screening. IDabs were isolated using two distinct antigens and affinities of isolated IDabs ranged between 20 nM and 200 nM. Moreover, IDabs selected for binding to the RAS protein could inhibit RAS-dependent oncogenic transformation of NIH3T3 cells. The IDab format is therefore ideal for in vivo intrabody use. This approach to intrabodies obviates the need for phage antibody libraries, avoids the requirement for production of antigen in vitro and allows for direct selection of intrabodies in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927545     DOI: 10.1016/s0022-2836(03)00836-2

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  33 in total

Review 1.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 2.  Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics.

Authors:  Boon Chin Heng; David Michael Kemeny; Hua Liu; Tong Cao
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

Review 3.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

4.  Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.

Authors:  Tomoyuki Tanaka; Terence H Rabbitts
Journal:  Nat Protoc       Date:  2009-12-17       Impact factor: 13.491

Review 5.  Genetically encodable fluorescent biosensors for tracking signaling dynamics in living cells.

Authors:  Robert H Newman; Matthew D Fosbrink; Jin Zhang
Journal:  Chem Rev       Date:  2011-04-01       Impact factor: 60.622

Review 6.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

7.  Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.

Authors:  Crystal M Vander Zanden; Eva Y Chi
Journal:  J Pharm Sci       Date:  2019-10-21       Impact factor: 3.534

8.  Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.

Authors:  Andrew S Dixon; Jonathan E Constance; Tomoyuki Tanaka; Terence H Rabbitts; Carol S Lim
Journal:  Pharm Res       Date:  2011-12-20       Impact factor: 4.200

9.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Authors:  Erik Kvam; Michael R Sierks; Charles B Shoemaker; Anne Messer
Journal:  Protein Eng Des Sel       Date:  2010-04-08       Impact factor: 1.650

10.  Selection of complementary single-variable domains for building monoclonal antibodies to native proteins.

Authors:  Tomoyuki Tanaka; Terence H Rabbitts
Journal:  Nucleic Acids Res       Date:  2009-02-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.